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ABSTRACT Three α-halogenated analogues of 3-(acetylhydroxyamino)propyl phosphonic acid 
(FR900098) have been synthesized from diethyl but-3-enylphosphonate using a previously described 
method for the α-halogenation of alkylphosphonates. These analogues were evaluated for antimalarial 
potential in vitro against Plasmodium falciparum and in vivo in the P. berghei mouse model. All three 
analogues showed higher in vitro and/or in vivo potency than the reference compounds. 
Introduction  
Despite huge efforts already taken, malaria still poses a major threat to public health and the economy 
of affected countries.1 With resistance emerging to virtually all available therapeutics, new antimalarials 
directed against new targets are highly awaited.2 In this respect, the non-mevalonate pathway for 
isoprenoid biosynthesis (also known as the MEP pathway) and considered essential in all malaria-
causing Plasmodium species constitutes a promising target.3
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 This pathway is unrelated to the classical 
mevalonate pathway (HMG-CoA reductase pathway) present in all higher eukaryotes and starts with the 
condensation of pyruvate and glyceraldehyde-3-phosphate to 1-deoxy-D-xylulose-5-phosphate (DOXP). 
Thus far, the second enzyme DOXP reductoisomerase (DXR), which catalyses the conversion of DOXP 
into 2-C-methyl-D-erythritol-3-phosphate (MEP), is the best investigated target in the search for new 
antibiotics, antimalarials and herbicides tackling the non-mevalonate pathway (Chart 1). 
 
Chart 1 
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Fosmidomycin (1) and its acetyl congener 2 (FR900098)4, structurally simple antibiotics isolated from 
Streptomyces cultures, are selective inhibitors of DXR5 and the former has been advanced to clinical 
trials in Gabon and Cameroon.6 Since the discovery of their antimalarial activity, different analogues of 
fosmidomycin / 2 have been synthesized in order to explore the S.A.R. and to develop more potent 
inhibitors. From these studies, it has become clear that neither the phosphonate4, 7, 8 nor the 
(retro)hydroxamate moiety9 can be replaced without drastic loss of activity. On the other hand, 
modification of the three-carbon spacer has resulted in DXR inhibitors that surpass fosmidomycin’s 
potency. For example, some α-aryl substituted fosmidomycin analogues proved to be more potent than 
fosmidomycin in inhibiting the growth of P. falciparum.10, 11 This advantage was especially apparent 
with electron withdrawing substituents, such as the 3,4-dichlorophenyl group in 3. One possible 
explanation for the observed S.A.R. in this series is that electron withdrawing substituents in α-position 
decrease the second pKa of the phosphonate group, which for that reason appears in its double-ionized 
form. Indeed, earlier S.A.R. studies at the enzyme level indicate that the presence of two ionizable 
groups on the phosphonate or phosphate probably plays a key role in the highly potent inhibition of 
DXR.7, 12 Consonantly with the hypothesis that increasing the acidity of the phosphonate moiety might 
confer improved activity, fosfoxacin (4), the phosphate analogue of fosmidomycin, and its acetyl 
congener were found to be more potent inhibitors of Synechocystis sp. PCC6803 DXR than 
fosmidomycin.7
Since the metabolic liability of the phosphate precludes its in vivo use as a DXR inhibitor, we decided 
to investigate if the phosphonate group of fosmidomycin could be manipulated to more accurately 
mimic the electronic nature of the phosphate moiety present in fosfoxacin and the DOXP substrate. 
Nieschalk et al.
   
13 showed that a monofluoromethylenephosphonate moiety can be a better phosphate 
mimic than the more popular difluoromethylenephosphonates often used for this goal, as the former one 
has a second pKa essentially equal to that of an organophosphate, whereas a 
difluoromethylenephosphonate is more acidic. Hence, we undertook the synthesis of α-halogenated 
fosmidomycin analogues 5a and b in which the required electron withdrawing effect comes from the 
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halogen instead of the sterically more demanding aromatic group as in 3, possibly resulting in a better fit 
into the active pocket of DXR.  
As stated above, modification of the N-formyl or N-acetyl retrohydroxamate in these structures usually 
results in a total loss of inhibitory activity.9 A notable exception to this ‘rule’ is the inversion of the 
retrohydroxamate into a hydroxamate as proven by Rohmer and coworkers.12, 14 A β-oxa analogue 
bearing an N-methylhydroxamate functionality showed even better DXR inhibiting properties,15
Results 
 hence 
we also envisaged the synthesis of α-fluoro hydroxamate 6. 
For the introduction of the respective halogens into 2, we adopted the strategy of Iorga et al.,16 based 
upon the attack of a deprotonated α-monosilylated alkylphosphonate on an electrophilic halogenation 
reagent, in casu hexachloroethane or N-fluorobenzenesulfonimide (NFBS).17
 
 This straightforward one-
pot strategy allowed for the synthesis of both envisaged precursors 10a and 10b with just a minor 
modification of the desilylation conditions (vide infra) and has several advantages such as high yield, 
high speed, ready availability of electrophilic halogenating reagents and easy elimination of byproducts. 
Unfortunately, this strategy proved to be very sensitive towards functionalities in the starting alkyl 
phosphonate, implying that all attempts to introduce a halogen onto a suitably protected fosmidomycin 
precursor using Iorga’s conditions remained unsuccessful (Scheme 1). 
Scheme 1. Substrates unsuccessfully tested in the halogenation reaction. 
P
O
R
OBn
N
Boc
OBoc
N
Boc
OTBDPS
N
Boc
R =
N
O
O
N3 OTBDMS
P
O
R
X
X = F, Cl
XEtO
EtO
EtO
EtO
 
First, three differently protected hydroxyamines, synthesized from diethyl 3-bromopropylphosphonate 
were tested. Unfortunately all reactions started to turn black after addition of the halogenation reagent, 
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resulting in complex reaction mixtures from which the desired compounds could not or only in very low 
yield be isolated. Assuming that it was the protected hydroxylamine functionality that did not withstand 
the reaction conditions, we turned to chemically more resistant (hydroxyl)amine precursors such as a 
phthalimide or azide group. Here again, the halogenation conditions caused decomposition of the 
starting materials and were also unsuccessful when applied on TBDMS-protected 
3-hydroxypropylphosphonate. These failures led us to explore a simpler phosphonate precursor, i.e. 
commercially available diethyl but-3-enyl phosphonate (7)18
 
, which could be halogenated in satisfying 
yields without noticeable breakdown to afford 10b. One side reaction observed in the synthesis of the 
α-chloro-derivative 10a, however, was the formation of conjugated diene 9 caused by elimination of 
chlorine when using the standard lithium ethoxide-ethanol deprotection for the TMS-group of 
intermediate 8. Hence, we decided to remove the installed TMS group by means of an acidic procedure 
(TBAF in acetic acid), resulting in the desired product 10 (Scheme 2). 
Scheme 2. Halogenation strategy with standard desilylation conditions (EtOLi/EtOH) resulting in 
elimination product 9 and alternative acidic procedure (TBAF/AcOH) towards 10a. 
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With the α-halogenated precursors 10a-b in hand, we then assembled the hydroxamate head group 
(Scheme 3). First the double bond was oxidized with NMO and osmium tetroxide as a catalyst. The 
resulting vicinal diol was then cleaved oxidatively with sodium periodate and the resulting aldehyde 
reduced with sodium borohydride to give alcohols 12a-b. 
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Scheme 3. Synthesis of α-chloro and α-fluoro analogues of FR900098
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aReagents and conditions: (a) (i) LDA, TMSCl, C2Cl6 or (PhSO2)2NF, THF, -78 °C, (ii) TBAF, 
AcOH, THF; (b) (i) OsO4, dioxane, (ii) NaIO4; (c) NaBH4, MeOH; (d) TsCl, Et3N, CH2Cl2; (e) 
BocNH(OBn), NaH, DMF; (f) TFA, CH2Cl2; (g) Ac2O, Et3N, DMAP, CH2Cl2; (h) H2, Pd/C, EtOAc; 
(i) (i) TMSBr, CH2Cl2, (ii) NH4OHaq.
Subsequently, the alcohols were converted into tosylates 13a-b, which were substituted with N-Boc 
O-benzyl-hydroxylamine. Treatment of 14a-b with trifluoroacetic acid in dichloromethane gave 
hydroxylamines 15a-b, which were acetylated with acetic anhydride. Finally, debenzylation of the 
retrohydroxamate by hydrogenation on palladium on carbon, followed by TMSBr-deprotection of the 
phosphonate esters and basic workup gave 5a-b as bisammonium salts. The synthesis of α-fluoro 
hydroxamate 6 could easily be elaborated from the α-fluoro precursor 10b (Scheme 2). Hydroboration 
of 10b gave rise to alcohol 18 which was oxidized with TEMPO-BAIB to carboxylic acid 19. This acid 
was activated with CDI followed by coupling with N-methyl O-benzylhydroxylamine to give 20, which 
was then deprotected in the same way as 16a-b to give 6 as the bisammonium salt. 
, THF  
Scheme 4. Synthesis of α-fluorohydroxamate 6a 
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In order to assess the influence of the introduced halogens on the ionization of these phosphonates, the 
pKa’s of compounds 5a and 5b as well as reference compound 2 were estimated from the pH 
dependence of their 31P chemical shift. Therefore, the 31P chemical shift of each compound was 
measured at different pH and plotted as a function of these pH values. The pKa of each compound is 
estimated to be at the pH of the inflection point of its titration curve. Of special interest here is the 
second pKa of each molecule, as the value of this pKa determines whether the phosphonate will be in its 
single- or double-ionized form at physiological pH. Therefore a cutout of the titration curves is 
displayed from which the pKa
Figure 1 Titration curves of compounds 2, 5a and 5b around their second equivalence point 
2 can be estimated (for the complete curves see Supporting Information). 
 
 
 From these figures, a pKa2 of 7.35 can be estimated for reference compound 2, whereas both the 
α-chlorinated analogue 5a and the α-fluorinated analogue 5b show a pKa2 of around 6. It can thus be 
concluded that introduction of a halogen in α-position of the phosphonate moiety indeed lowered the 
pKa2 of those compounds to a pKa2 comparable to that of a phosphate13
The title compounds were tested in duplicate for their inhibitory effect against intraerythrocytic forms of 
P. falciparum (strains GHA and K1) using a microdilution assay.
 and that, at a physiological pH, 
they will be present in their double-ionized form.  
19 The results are summarized in 
Table 1. All three analogues show submicromolar activity on both strains and appear to be five- to 
six-fold more active than the parent compound fosmidomycin and slightly superior to 2 on the K1 strain. 
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Table 1. In vitro growth inhibition of the P. falciparum strains GHA and K1 
Compound 
IC50
Pf-GHA 
 (µM) 
Pf-K1 
 Fosmidomycin (1) - 1.73 ± 0.89 
 2 - 0.42 ± 0.17 
 3 0.60 ± 0.01 0.16 ± 0.01 
 5a 0.82 ± 0.10 0.30 ± 0.06 
 5b 0.70 ± 0.08 0.29 ± 0.06 
 6 0.73 ± 0.11 0.31 ± 0.07 
 
The initial α-aryl derivative 3 and the fluorinated analogues 5b and 6 were subsequently evaluated in 
vivo in the P. berghei (GFP ANKA-strain) acute mouse model after intraperitoneal dosing at 50 mg/kg 
for 5 consecutive days. Chloroquine (10 mg/kg for 5 days) was included as reference treatment. The 
animals were observed for the occurrence/presence of clinical or adverse effects during the course of the 
experiment. In case of very severe clinical signs, either due to toxicity or malaria, animals were 
euthanized for welfare reasons. Parasitaemia was determined on days 4, 7 and 14 on surviving animals 
using flow cytometry (10 µL blood in 2000 µL PBS). Percentage reduction of parasitaemia compared to 
vehicle-treated infected controls is used as a measure for drug activity and the mean survival time 
(MST) was calculated (Table 2). Compound 3 did not show any relevant activity. On the other hand, 
compound 6 resulted in 85% suppression of parasitaemia at 4dpi, which dropped to 42% at 7dpi and 
41% at 14dpi. The mean survival time was 11.7 days. Compound 5b resulted in 88% suppression of 
parasitaemia at 4dpi, which after ending the treatment also dropped to 62% at 7dpi and 32% at 14dpi. 
The overall MST was 15.8 days. These data clearly demonstrate that all three synthesized compounds 
have promising in vitro activity and that compounds 5b and 6 surpass the antimalarial activity of (2) in 
vivo. 
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Table 2. Survivors and mean survival time (MST in days) in the P. berghei (GFP ANKA-strain) acute 
mouse model. 
Treatment Parasitaemia 
suppression 
(day 4) 
Survivors 
MST 
(IP for 5 consecutive days) day 7 day 11 day 14 Day 25 
Vehicle 0 1/6 1/6 1/6 0/6 8.5 
Chloroquine (10 mg/kg) 100 6/6 6/6 6/6 3/6 20.7 
Fosmidomycin (1) (50 mg/kg) 82 6/6 4/6 3/6 nd 11.5 
2 (50 mg/kg) 93 6/6 3/6 2/6 nd 10.8 
3 (50 mg/kg) 46 4/5 0/5 0/5 0/5 7.0 
5b (50 mg/kg) 88 4/4 2/4 2/4 0/4 15.8 
6 (50 mg/kg) 85 2/3 2/3 1/3 0/3 11.7 
 
In summary, three α-halogenated analogues of 2 were synthesized and surpass or equal fosmidomycin 
or 2 in both in vitro and in vivo antimalarial activity. These findings consolidate the assumption that 
electron withdrawing substituents, causing a decrease in phosphonate pKa, favor the antimalarial 
activity of fosmidomycin analogues. Furthermore, we provided a new example of a fosmidomycin 
analogue in which the (N-formyl-N-hydroxy)amino moiety, involved in a chelating interaction with a 
Mn2+
An important outcome of the current study is that the promising in vitro activity of the α-fluorinated 
analogues 5b and 6 is reflected in the P. berghei acute mouse model, while the α-aryl fosmidomycin 
analogue 3 failed to show significant in vivo activity despite its promising in vitro activity.   
 cation, can be replaced by a N-hydroxy-N-methylamide group as found in 6. This opens new 
perspectives to combine other favorable α-modifications with a hydroxamate moiety.  
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Exper imental Section 
Synthesis. General. 1H, 13C, 19F and 31PNMR spectra were recorded in CDCl3, acetone-d6, 
DMSO-d6 or D2O on a Varian Mercury 300 spectrometer. Chemical shifts are given in parts per million 
(ppm) (δ relative to residual solvent peak for 1H and 13C and to external D3PO4 for 31P). Silica gel (60 
Å, 0.063 – 0.200 mm) was purchased from Biosolve. All solvents and chemicals were used as purchased 
unless otherwise stated. Purity of the final compounds was deduced from clean 1H, 13C and 31
(±)-3-(N-hydroxyacetamido)-1-chloropropylphosphonic acid, bisammonium salt (5a). To a 
solution of 17a (150 mg; 0.52 mmol) in dry dichloromethane (5 mL) was added TMSBr (0.7 mL, 5.20 
mmol) while stirring at 0 °C. After 45 minutes the ice bath was removed and stirring was continued at 
room temperature. After three days, 
P NMR 
spectra, high resolution mass spectra and assessed by LC-DAD-MS. Reversed phase chromatograms 
were recorded on a Phenomenex Luna C-18 2.5 µm particle (100 x 2.00 mm) column or a Phenomenex 
Luna HILIC 200A 3µm particle (100 x 2.00 mm) column in a Waters Alliance 2695 XE HPLC system 
spectrometer with quaternary pump, DAD detector and coupled to a Waters LCT Premier XE 
orthogonal time-of-flight spectrometer with API-ES source. High resolution mass spectroscopy spectra 
for all compounds were also recorded on a Waters LCT Premier XE orthogonal time-of-flight 
spectrometer with API-ES source. Purity of all final compounds was 95% or higher. 
31P-NMR revealed the presence of uncompletely deprotected 
material, so another 0.2 mL of TMSBr was added. After another three days of stirring at room 
temperature, the volatiles were removed in vacuo, the residue was redissolved in 5% aqueous ammonia 
and washed with diethyl ether. The aqueous phase was then lyophilized to give 138 mg of a very 
hygroscopic, off-white powder. 1H NMR (300.01 MHz, D2O) δ 1.92-2.57 (2H, m), 2.16 (3H, s), 3.71-
3.92 (2H, m), 3.92-4.06 (1H, m); 13C NMR (75.44 MHz, D2O): δ 19.5 (CH3), 30.7 (CH2), 45.9 (CH2, d, 
3JPC = 13.0 Hz), 54.8 (CClH, d, 1JPC = 139.0 Hz), 174.0 (C=O); 31P NMR (121.45 MHz, DMSO-d6) 
δ 11.85; HRMS (ESI) m/z 232.0135 [(M+H)+, calcd for C5H12ClNO5P+ 232.0136]. 
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(±)-3-(N-hydroxyacetamido)-1-fluoropropylphosphonic acid, bisammonium salt (5b). To a 
solution of 17b (223 mg, 0.82 mmol) in dry dichloromethane (8 mL) was added TMSBr (1.1 mL, 8.2 
mmol) while stirring at 0 °C. After 45 minutes the icebath was removed and stirring was continued at 
room temperature. After 3 days, 31P NMR revealed the presence of uncompletely deprotected material, 
so another 0.2mL of TMSBr was added. After another 4 days of stirring at room temperature, the 
volatiles were removed in vacuo, the residue was redissolved in 5% aqueous ammonia and washed with 
diethyl ether. The aqueous phase was then lyophilized to give 207 mg of 5b as a very hygroscopic, off-
white powder. 1H NMR (300.01 MHz, D2O) δ 1.96-2.22 (2H, m), 2.11 (3H, s), 3.58-4.00 (2H, m), 4.33-
4.64 (1H, m); 13C NMR (75.44 MHz, D2O): δ 19.5 (CH3), 28.4 (CH2, d, 2JCF = 20.2 Hz), 45.0 (CH2, d, 
3JPC = 3.6 Hz), 90.7 (CHF, dd, 1JCF = 171.0 Hz, 1JPC = 154.0 Hz), 174.0 (C=O); 31P NMR (121.45 MHz, 
D2O) δ 11.80 (d, 2JPF = 62.3 Hz); HRMS (ESI) m/z 216.0455 [(M+H)+, calcd for C5H12FNO5P+
(±)-3-(N-hydroxy-N-methylcarbamoyl)-1-fluoropropylphosphonic acid, bisammonium salt (6). 
21 (119 mg, 0.44 mmol) was dissolved in dry dichloromethane under inert atmosphere and cooled to 
0 °C. TMSBr (0.6 mL, 4.4 mmol) was added dropwise while stirring. The icebath was removed and the 
reaction was stirred at room temperature. After 24 hours another 0.3 mL of TMSBr were added and the 
reaction was stirred for another 4 days. The volatiles were removed in vacuo, the crude material was 
dissolved in 5% aqueous ammonia and washed with diethyl ether. Lyophilisation of the ammonia 
solution yielded the product as a brown solid in quantitative yield.
 
216.0432]. 
 1H NMR (300.01 MHz, D2O) δ 1.82-
2.00 (2H, m), 2.30-2.62 (2H, m), 3.07 (3H, s), 4.18-4.45 (1H, m); 13C NMR (75.44 MHz, D2O) 
δ 27.0 (CH2, d, 2JCF = 19.6 Hz), 28.5 (CH2, d, 3JPC = 1.0 Hz), 36.1 (CH3), 92.9 (CHF, dd, 1JCF = 171.1 
Hz, 1JPC = 153.7 Hz), 175.5 (C=O); 31P NMR (121.45 MHz, D2O) δ 11.74 (d, 2JPF = 63.27 Hz); HRMS 
(ESI) m/z 216.0437 [(M+H)+, calcd for C5H12FNO5P+ 216.0432]. 
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